SOX9 and prostate cancer: Remarkably, our data suggest that SOX9 may provide substantial additional prognostic information beyond PTEN deletion—one of the strongest known single prognosticators in prostate cancer, but at the same time also demonstrate that the value of SOX9 as a putative molecular marker is limited to the small subset of about 10–15% of prostate cancers harboring both ERG-fusion and PTEN deletion.